FDA Removes Tirzepatide from the Shortage List: What This Means

The FDA has officially removed Tirzepatide from the drug shortage list. While this decision sets a timeline that will impact patients who rely on compounded versions of this essential medication, there is currently a court stay in place that could impact the enforcement of these restrictions.

As of now, compounded Tirzepatide may no longer be allowed after February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities. While this decision affects compounded Tirzepatide, it’s clear that Semaglutide may face similar regulatory action soon.

Why This Matters

This decision underscores the urgent need for permanent, affordable solutions for patients who rely on GLP-1 medications to manage chronic diseases. Compounding pharmacies provide critical access to affordable options, but they may no longer be allowed to produce these medications.

The FDA must act to ensure that at least one affordable option is available to patients. Whether through compounding pharmacies, FDA-approved generics, lower drug prices, or mandatory insurance coverage, we need lasting solutions so no one is left without access to these essential treatments.

Thank You for Your Efforts

Getting this far wouldn’t have been possible without each and every one of you who signed and shared the petition. Your voices are making a difference, and together, we’ve already brought national attention to this important fight.

In just one month, we’ve achieved 15,000 signatures and earned 3 media mentions, (see the latest mention here) taking the petition to the national stage. Imagine what we can accomplish by February 19th with your continued support.

From the bottom of our hearts, thank you for your unwavering support and dedication. We wish you a Merry Christmas and a joyful holiday season filled with hope and love. Let’s keep working together in the months ahead to secure permanent, affordable access for all.

Happy Holidays, and thank you!